Source

The thesis was right. The vehicle was wrong. We pivot from BRBR (-68% from thesis target) to HIMS (+49% 30D, validated via Discord intake) as the actual cultural beneficiary. FDA investigation is the open risk on HIMS; size accordingly.

What we got right

GLP-1 drugs are creating a medically-mandated protein/health demand loop. 86% of Americans adding protein. 12% on GLP-1. The cultural cascade is real. Demand for accessible weight-loss/health interventions is structural, not cyclical.

What we got wrong

We picked BellRing Brands (BRBR) as the pure-play beneficiary in April based on a "Wall Street narrative gap" — the analyst whey-cost narrative against the cultural truth. The numbers since:

• BRBR thesis target: $46.88 (April 2026)
• BRBR today: ~$15 (RSI 38, strong-down trend)
• Actual return: -68% from thesis target
• HIMS over the same period: +47% to +49%

The cultural cascade picked HIMS. We were watching the wrong window.

The lesson

Bet on the channel, not the SKU. BellRing sold protein powder. HIMS sells access — direct-to-consumer GLP-1 via compounding pharmacy partnerships. The patient sees a HIMS ad, books a video consult, and gets a GLP-1 prescription delivered. That's the cultural-arbitrage chokepoint. Selling more protein into a market saturated with supplement brands wasn't the same kind of asymmetric position.

Future cultural-arbitrage theses should ask:...